Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €0.58 EUR
Change Today -0.02 / -3.33%
Volume 235.1K
As of 11:37 AM 09/1/15 All times are local (Market data is delayed by at least 15 minutes).

diaxonhit (ALEHT) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/22/15 - €1.04
52 Week Low
10/15/14 - €0.47
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for DIAXONHIT (ALEHT)

Related News

No related news articles were found.

diaxonhit (ALEHT) Related Businessweek News

No Related Businessweek News Found

diaxonhit (ALEHT) Details

Diaxonhit discovers and commercializes specialty diagnostic products in the areas of transplantation, infectious diseases, and cancer diagnosis. It offers Tetanus Quick Stick, a proprietary test that is used in emergency clinics for the evaluation of the protective status of a patient against tetanus. The company's in-house development products include the BJI InoPlex, a multiplex serological test used for the diagnosis of prosthetic joint infections; and Dx15, a test for the diagnosis of thyroid cancer. Its licensed products comprise AlloMap, a gene-expression profiling based blood test for regular and non-invasive surveillance of heart transplant recipients for acute cellular rejection. Diaxonhit was founded in 1997 and is headquartered in Paris, France.

85 Employees
Last Reported Date: 04/30/15
Founded in 1997

diaxonhit (ALEHT) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

diaxonhit (ALEHT) Key Developments

DIAXONHIT Encourages Results of the First Clinical Study of the VAC-3S Vaccine against HIV, for Which Diaxonhit Develops a Companion Diagnostic

DIAXONHIT announced that InnaVirVax, the company with which it currently develops a companion diagnostic for the VAC-3S vaccine within the PROTHEVIH program, released encouraging results of the IVVAC-3S/P1 clinical study during the International AIDS Society Symposium held in Vancouver on July 18 and 19, 2015. Encouraging results of the IVVAC-3S/P1 study: The primary endpoint of this phase 1 study was met. The VAC-3S immunotherapy was well tolerated and immune response was observed as expected with a strength clearly linked to dose. Additionally, vaccination with VAC-3S triggered favorable immunovirologic effects, as measured by the leading four biomarkers of disease progression. Correlated with immune response to VAC-3S, a decrease in proviral DNA, the most studied biomarker of viral load, was observed. Furthermore, the following observations were made in responders 24 weeks after initial vaccination: The percentage of CD4+ T lymphocytes, usually destroyed by the HIV virus, increased (biomarker of such T lymphocytes reservoir); The percentage of CD8+ T lymphocytes decreased (biomarker of immune activation); The ratio CD4/CD8 increased (biomarker of immune system restoration in HIV infected patients). Such results are promising. InnaVirVax indicated that if the favorable changes in these four biomarkers were confirmed in other studies with a higher number of patients, it could potentially lead to VAC-3S being used to restore immune functions in immunodeficient patients. This positions VAC-3S vaccination as a functional cure in order to enable HIV infected patients to control their viral load without antiretroviral treatments. Synergistically with VAC-3S development, DIAXONHIT is currently developing two tests with its diagnostic know-how in the PROTHEVIH consortium: DIAG-3S, a diagnostic test for the detection of anti-3S antibodies naturally secreted by patients infected by the HIV-1 virus. One of DIAXONHIT's objectives is to validate the use of the level of natural anti-3S antibodies measured by this test as an early marker of disease progression, thus enabling optimized care of HIV-1 infected patients. The DIAG-3S prototype test should be completed during the first half of 2016. Upon completion and validation, commercialization of the test could start independently of the VAC-3S vaccine development; CO-3S, a companion diagnostic for the VAC-3S vaccine which measures the level of anti-3S antibodies in vaccinated patients. This test will enable doctors to measure the immune response to the vaccine therapy, and adjust it accordingly.

Diaxonhit Presents at Second French Life Science Days Conference, Jun-17-2015

Diaxonhit Presents at Second French Life Science Days Conference, Jun-17-2015 . Venue: W Hotel, 541 Lexington Avenue, New York, NY 10022, United States.

DIAXONHIT Announces the Results of a European-Based Clinical Study Confirming the Utility and Performance of the AlloMap® Test

DIAXONHIT announced the results of a European-based clinical study confirming the utility and performance of the AlloMap® test. Results from the CARGO II study, which evaluated the use of AlloMap in 594 heart transplant patients, demonstrated performance similar to previously published experience in the United States. Following a heart transplant procedure, this test enables routine, non-invasive surveillance of acute cellular rejection, thereby assisting clinicians in the care and management of patients. CARGO II (Cardiac Allograft Rejection Gene Expression Observational II) is a prospective, observational, multicenter clinical study. Its main objective was to confirm the results of the first CARGO study, which was used to validate the performance of the AlloMap® test with US patients. CARGO II involved more than 17 centers, 13 of which were located in Europe. These results were the basis for the test's 510K filing with the FDA and CE marking. In the study, blood samples for AlloMap® testing were collected during post-transplant surveillance visits beginning at least 55 days after heart transplantation, with or without cardiac biopsy. After analyzing the samples, the test result was provided as a unique score ranging from 0 to 40, with high values indicating a greater risk of acute cellular rejection. Moderate to severe acute cellular rejection (i.e., histopathology analysis of biopsies showing a grade greater than or equal to 3A according to the ISHLT grading system) were reported by pathologists in 106 out of 3,324 biopsies (3.2%), in 79 out of 594 patients (13.0%). Taking into account these observations, the study shows that the negative predictive value of AlloMap® is greater or equal to 99.0% for AlloMap® scores less than 34. This threshold is therefore associated with a low risk of moderate to severe acute cellular heart graft rejection. Ultimately, the CARGO II results confirm those of the initial CARGO study performed in the United States and demonstrate the utility of AlloMap in ruling out moderate to severe acute cellular allograft rejection.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALEHT:FP €0.58 EUR -0.02

ALEHT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
NEL ASA 1.98 NOK -0.01
View Industry Companies

Industry Analysis


Industry Average

Valuation ALEHT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.1x
Price/Book 1.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DIAXONHIT, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at